Recherche

Sélectionner un mot

L'échoendoscopie ou EBUS (pour endobronchial ultrasound) est une exploration de l'arbre trachéo-bronchique qui combine une endoscopie et l'échographie. Elle permet de repérer...

En savoir plus

Augmentation de volume d'un organe ou d'un tissu, due à une prolifération de cellules organiques qui forment un nouveau tissu. Une Tumeur est soit maligne (synonyme de cancer),...

En savoir plus

Le Cancer est une maladie caractérisée par une prolifération cellulaire anormale au sein d'un tissu normal de l'organisme, pouvant aller jusqu’à menacer la survie de ce...

En savoir plus

Une Thérapie désigne un ensemble de mesures appliquées par un thérapeute à une personne souffrant d'un problème de santé ou d'une maladie, dans le but de l'aider à...

En savoir plus

La Thyroïde est une grande glande située dans le cou. Sous l'effet de l'iode apporté par l'alimentation, elle synthétise des hormones essentielles au bon fonctionnement du...

En savoir plus

Ce syndrome est dû à une tumeur cancéreuse (cancer du poumon) se situant dans la région supérieure du thorax. Les cellules cancéreuses envahissent les nerfs qui constituent...

En savoir plus

Cage Ostéo-musculo-ligamentaire situé entre le cou et l’abdomen. Le Thorax contient essentiellement le cœur et les poumons, mais également l’œsophage et des gros...

En savoir plus

La tomographie par émission de positons (TEP) est une méthode d'imagerie médicale pratiquée par les spécialistes en médecine nucléaire qui permet de mesurer en trois...

En savoir plus

Région médiane du thorax, situé entre les poumons, contenant le cœur et les gros vaisseaux, la trachée et les bronches extrapulmonaires, l’œsophage, de nombreux vaisseaux...

En savoir plus

Un Symptôme représente une des manifestations subjectives d'une maladie ou d'un processus pathologique, tel qu'exprimé par le patient. En général, pour une pathologie...

En savoir plus

L'échographie Doppler vasculaire est un examen qui permet, en utilisant une sonde émettrice réceptrice à ultrasons de mesurer la vitesse de la colonne sanguine (du flux...

En savoir plus

La Scintigraphie est une méthode d'imagerie médicale qui procède par l'administration, dans l'organisme, d'isotopes radioactifs afin de produire une image médicale par la...

En savoir plus

 

JE prends contact

Prendre Rendez-Vous

01 40 94 24 24

Une question par mail

Un institut unique

Dr. Benjamin Besse

Date of birth : June 12, 1974
Place of birth : Suresnes – France
Citizen ship : French

Institut Gustave Roussy
Ordre des Médecins (Val de Marne) : 14746

Education and medical activites

MD degree :

– On going : Head of the thoracic cancer unit, Department of Medicine, Institut Gustave Roussy
– MD thesis: Comparative histology of residual masses in patients with biologic complete remission after platinum-based chemotherapy for non seminomatous germ cell carcinomas.
– Medical Oncology Residency and Fellowship (Internat des Hôpitaux de Paris, 1999-2005)
– School of Medicine : René-Descartes University, Paris V, France (1992 – 1999).

PhD degree :

– PhD thesis : apoptosis biomarkers and non small cell lung cancer, 2008, Paris XI.
– Research laboratory :
– Institut Gustave Roussy, Villejuif, France, 2004-present.
– Institut Català d’Oncologia, Hospital Germans Trial y Pujol, Badalona, Spain 2003-2004.
– M.S. degree : APAF 1 (apoptosic protease activating factor 1) as a prognostic factor in NSCLC, Paris Sud University (Paris XI) (2003).
– Bachelor’s of Science : in Physiology and immunology, René-Descartes University, Paris V (2001).

Clinical Trials :

– Principal investigator of the M200-1211 study (PDL Biopharma)
– Co-Investigator of studies with the following compounds : Enzastaurine (H6Q-MC-JCBT, Lilly), AMG 951 (20050190, Amgen), PHA-739358 (AURA-6202-006-P1, Nerviano), VEGF-Trap (AVE0005, ARD6123, Aventis), RAD001 (CRAD2111, C2235) Novartis), HKI-272 (3144A1-WW-200, Wyeth), PTKZK (GOAL, Bayer), Sunitinib (A6181057, Pfizer), Bortezomib (Peak, LUC1001, LUC 2001, Janssen Cilag)

Others :

– European Certification in Medical Oncology (ESMO), 2005
– ASCO merit award, 2005
– 4th AACR-ASCO-FECS Workshop on methods in clinical cancer research (Flims, 2002)
– Baccalaureate in Sciences : Lycée Carnot, High School, Paris, France (1992).
– ESMO fellowship for translational research, 2004.

Works

Paper

  • The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. J Clin Oncol. 2010 Nov 15. [Epub ahead of print]
  • [Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]. Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P. Rev Pneumol Clin. 2010 Sep;66(4):255-9. Epub 2010 Sep 15. French.
  • ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Besse B, Massard C, Haddad V, Andre F, Dunant A, Pirker R, Olaussen KA, Brambilla E, Fouret P, Soria JC. Ann Oncol. 2010 Aug 26. [Epub ahead of print]
  • [Internet as a tool in oncology: critical analysis.] Rousseau B, Besse B. Bull Cancer. 2010 Jul 26. [Epub ahead of print] French.
  • Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor. Prulière-Escabasse V, Gomez-Roca C, Escudier E, Coste A, Besse B, Massard C, Soria JC. Onkologie. 2010;33(7):401-2. Epub 2010 Jun 22.
  • A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. J Thorac Oncol. 2010 Jul;5(7):1054-9.
  • Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC. Ann Oncol. 2010 Jun;21(6):1385-7.
  • Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. J Clin Oncol. 2010 Jun 20;28(18):3076-83. Epub 2010 May 17.
  • Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Massard C, Plantade A, Gross-Goupil M, Loriot Y, Besse B, Raynard B, Blot F, Antoun S, Nitenberg G, Escudier B, Fizazi K. Ann Oncol. 2010 Feb 24. [Epub ahead of print]
  • Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. J Clin Oncol. 2010 Mar 20;28(9):1527-33. Epub 2010 Feb 16.
  • [Molecular targeted therapies in small-cell lung cancer]. Levy A, Malouf GG, Besse B, Massard C, Soria JC. Bull Cancer. 2010 May;97(5):535-45.
  • Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Barlési F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, Dansin E, Ferretti G, Gaubert JY, Gervais R, Lacombe C, Loundou A, Moro-Sibilot D, Planchard D, Scherpereel A, Menu Y. Ann Oncol. 2010 Jan 11.
  • Bevacizumab safety in patients with central nervous system metastases. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Clin Cancer Res. 2010 Jan 1;16(1):269-78. Epub 2009 Dec 22.
  • [Lung cancer: an update in 2010.] Besse B, Vignot S, Soria JC. Bull Cancer. 2009 Dec 22. [Epub ahead of print]
  • Quantification of circulating vascular endothelial growth factor receptor-3-positive lymphatic/vascular endothelial progenitor cells. Farace F, Taylor M, Rössler J, Loriot Y, Besse B. Clin Cancer Res. 2009 Nov 1;15(21):6740; author reply 6740-1. Epub 2009 Oct 27.
  • Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. Massard C, Loc PT, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC. J Thorac Oncol. 2009 Dec;4(12):1504-10.
  • Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC. J Thorac Oncol. 2009 Aug 14. [Epub ahead of print]
  • Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. Besse B, Le Chevalier T. Oncology (Williston Park). 2009 May;23(6):520-7.
  • Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C. Br J Dermatol. 2009 May 21.
  • QT interval prolongation among patients treated with angiogenesis inhibitors. Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, Besse B, Berthelot E, Boccara F, Soria JC. Target Oncol. 2009 Apr;4(2):89-97.
  • [Pronostic and predictive factors in lung cancer.] Marijon H, Bouyon A, Vignot S, Besse B. Bull Cancer. 2009 Apr;96(4):391-404
  • Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Invest New Drugs. 2009 Apr 3. [Epub ahead of print]
  • The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P. Ann Oncol. 2009 Mar 17. [Epub ahead of print]
  • Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. Besse B, Grunenwald D, Fléchon A, Caty A, Chevreau C, Culine S, Théodore C, Fizazi K. J Thorac Cardiovasc Surg. 2009 Feb;137(2):448-52.
  • Bevacizumab and radiotherapy]. Blanchard P, Besse B, Deutsch E. Rev Mal Respir. 2008 Dec;25(10):1319-21.
    [Towards customized therapy for non small cell lung cancer]. Planchard D, Besse B. Bull Cancer. 2008 Oct;95(10):951-8.
  • Hypokalemia, metabolic alkalosis, and hypertension in a lung cancer patient. Izzedine H, Besse B, Lazareth A, Bourry EF, Soria JC. Kidney Int. 2008 Aug 27. [Epub ahead of print]
  • Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? Besse B, Le Chevalier T. J Clin Oncol. 2008 Nov 1;26(31):5014-7. Epub 2008 Sep 22.
  • Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P. Clin Cancer Res. 2008 Jul 1;14(13):4096-102.
  • [Management of targeted molecular therapies toxicities in thoracic cancerology.] Rajpar S, Osio A, Besse B. Rev Pneumol Clin. 2008 Apr;64(2):104-10. Epub 2008 Jun 6. French.
  • [Thrombosis and lung cancer.] Girard P, Raynaud C, Meyer G, Parent F, Besse B. Rev Pneumol Clin. 2008 Apr;64(2):85-91. Epub 2008 Jun 5.
  • Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. Wagner M, Besse B, Balleyguier C, Soria JC. J Thorac Oncol. 2008 Jun;3(6):677-9.
  • [The role of radiotherapy in the management of patients with small cell lung cancer]. Daveau C, Le Péchoux C, Besse B, Ferreira I, Amarouch A, Vicenzi L, Elloumi F, Roberti E, Bretel JJ. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S171-9. Review.
  • Nonapoptotic role for apaf-1 in the DNA damage checkpoint. Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, Boehrer S, Pauleau AL, Rosselli F, D’Amelio M, Amendola R, Castedo M, Hengartner M, Soria JC, Cecconi F, Kroemer G. Mol Cell. 2007 Nov 30;28(4):624-37.
  • [Standards, Options and Recommendations (SOR) for the perioperative treatment of operable patients with resecable non small cell lung cancer.] Besse B, Depierre A, Guillo S, Séblain-El Guerche C, Douillard JY, Giniès A, Hennequin C, Le Péchoux C, Milleron B, Moro-Sibilot D, Mouillefarine P, Quoix E, Régnard JF, Riquet M, Vaylet F, Zalcman G. Bull Cancer. 2007; 94 (10) 887-96
  • [Angiogenesis targeting in lung cancers]. Planchard D, Besse B. Bull Cancer. 2007;94 Suppl FMC Targeted Therapy:F217-22.
  • [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. Italiano A, Besse B, Planchard D, Soria JC. Bull Cancer. 2007;94 Suppl FMC Targeted Therapy:F177-88. French.
  • Targeted therapies in lung cancer. Besse B, Ropert S, Soria JC. Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42.
    [Gemcitabine and non small-cell lung cancer]. Vignot S, Besse B .Bull Cancer. 2007;94 Spec No Actualites:S95-103.
  • Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, Girard P, Validire P, Breau JL, Bernaudin JF, Soria JC. Clin Cancer Res. 2007 Aug 15;13(16):4825-31.
  • [Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient]. Besse B, Soria JC. Rev Prat. 2007 Feb 28;57(4):429-40; quiz 440.
  • Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S. Anticancer Res. 2007 Jan-Feb;27(1B):547-55.
  • [Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung]. Le Pechoux C, Besse B, Ferreira I, Bretel JJ, Bruna A, Mazeron R, Amarouch A, Roberti E. Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S188-16S197.
  • [Neoadjuvant chemotherapy in non small cell lung cancer]. Besse B, Vignot S, Le Chevalier T. Bull Cancer. 2006 Nov 1;93(11):1087-92.
  • Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study. Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, Goupil A, Turpin F, Urien S, Lokiec F. Cancer Chemother Pharmacol. 2006 Nov 15; [Epub ahead of print]
  • [Lung cancer: is there a place for elective nodal irradiation?] Le Pechoux C, Ferreira I, Bruna A, Roberti E, Besse B, Bretel JJ. Cancer Radiother. 2006 Nov;10(6-7):354-60. Epub 2006 Oct 10.
  • Targeting angiogenesis with oral agents. Ann Oncol. Besse B, Armand JP, Soria JC. 2006 Sep;17 Suppl 10:x71-x75.
  • [Cannabis and cancer]. Vignot S, Besse B, de la Motte Rouge T, Massard C, Spano JP, Karila L, AERIO. Bull Cancer. 2006 Feb 1;93(2):163-70.
  • [EGFR-targeted therapies: what’s new?]. Vignot S, Besse B, Soria JC, Milano G, Spano JP. Bull Cancer. 2006 Jan 1;93(1):13-8.
  • Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama KI, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ. Lung Cancer. 2005 Jul 9; [Epub ahead of print]
  • Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy. Besse B, Soria JC, Le Chevalier T. Ann Oncol. 2005 Jun 9; [Epub ahead of print]
  • Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Erman M, Grunenwald D, Penault-Llorca F, Grenier J, Besse B, Validire P, Morat L, Girard P, Le Chevalier T, Sabatier L, Soria JC. Lung Cancer. 2005 Mar;47(3):315-23.
  • The promise of pharmacogenomics: gemcitabine and pemetrexed. Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. Oncology (Huntingt). 2004 Nov;18(13 Suppl 8):70-6.
  • Review Nuclear localization of Apaf-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. B.Besse, C.Candé, J-P.Spano, A.Martin, D.Khayat, T.Le Chevalier, T.Tursz , L.Sabatier, J-C.Soria, G.Kroemer. Clin Cancer Res. 2004 Sep 1;10(17):5665-9.
  • Les mutations de l’Iressa. [Selection of patients responsive to Iressa(R)]. Besse B, Le Chevalier T, Soria JC. Med Sci (Paris). 2004 Aug-Sep;20(8-9):750-1.
  • Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC. Ann Oncol. 2004 Apr;15(4):613-7
  • Gemcitabine and breast cancer. Besse B, Spano JP. Bull Cancer 2002; 89: 7 – 14.

Communications

  • Poster at the 12th World Lung Cancer Congres, Seoul, 2007 (Abstract 4524)
  • Posters at the 43th ASCO Congress, Chicago, 2007 : 7581 (fisrt author), 7655 (second author), 7541 (second author)
  • ESMO Conference Lugano (ECLU) 2007 : Co-chair session « highlights in lung cancer », 6 jul 2007 – Invited speaker “Questions from a yong medical oncologist” (session highlights in lung cancer) 6 jul 07 – Chair session “Hot topics in Lung Cancer” 8 jul 2007 – Invited speaker “Molecular targeted agents in lung cancer” session “Hot topics in Lung Cancer” 8 jul 07
  • ESMO International Symposium (EIS), chest tumors, Geneve, Apr 1st 07, invited speaker : clinical case « A 38-year old woman, non-smoker, adenocarcinoma, multiple lung lesions »
  • Poster – discussion and Poster at the 31th ESMO Congress, Istambul, 2006 (Abstracts 730 and 560)
  • Poster – discussion at the 41th ASCO Congress, Orlando, 2005 (Abstract 4524)
  • Oral presentation at the 2nd educational symposium of the Spanish Lung Cancer Group, Bilbao, Spain, 2004.
  • Oral presentation at the 9th Central European Lung Cancer Conference, Gdansk, Poland, 2004.
  • Poster-discussion at the 25th ESMO Congress, Vienna, 2004 (abstract 62PD).
  • Abstract at the 36th ASCO Congress, Chicago, 2003 (abstract 3554).
  • Poster at the 23rd ESMO Congress, Hamburg, Germany, 2000 (abstract 643).

Book

  • Other targeted agents in NSCLC. Besse B. Soria J.C. Lung Cancer: Prevention, Management and Emerging. Edited by David Stewart. Humana Press. 2010.
  • Thérapies moléculaires ciblées et tumeurs thoraciques rares. J. Margery, B. Besse, P. Ruffié. Thérapie moléculaire ciblée en oncologie thoracique. Coordonné par Jean-Charles SORIA. Collection Mise au point. John Libbey Eurotext 2008.
  • Cancer bronchique non à petites cellules et thérapeutiques ciblant l’EGFR : le point en 2008. B. Besse, J.-C. Soria. Thérapie moléculaire ciblée en oncologie thoracique. Coordonné par Jean-Charles SORIA. Collection Mise au point. John Libbey Eurotext 2008.
  • Molécules inhibitrices des récepteurs du VEGF. Y. Loriot et B. Besse. Les thérapies ciblées. Coordonné par le Dr Gaëtan des Guetz et le Pr Jean-Yves Blay Springer 2008.
  • Collection 24 heures. Coordinators : Benjamin Bajer and Florian Naudet. 12 clinical cases for Medical fellows. 2008.
  • Cancers Bronchiques Opérables, John Libbey Eurotext, 2008. Coordinator.
  • Adjuvant chemotherapy following surgery for lung cancer. B.Besse and T.Le Chevalier. Lung Cancer, edited by J.A.Roth, J.D.Cox and W.Ki Hong. Third edition. Blackwell publishing. 2007.
  • Coordinator of the French Guidelines 2007 SOR (Standards, Options, Recommandations) : [perioperative chemotherapy in resectable NSCLC patients]
  • ERCC1 et cancer bronchique – Eurocancer 2007 – John Libbey Eurotext, Paris, pp.105-6.
  • Thérapies ciblées et cancer bronchique : quelle perspective ? – Eurocancer 2007 – John Libbey Eurotext, Paris, pp.215-7.
  • Clinical cases in Oncology. Reference Internat 100 dossiers, J.B.Baillière edition, 2005.
  • Pulmonary infections. ESMO Handbook of oncological emergencies. Besse B. Taylor & Francis, UK. 2005.
  • Module 10 : Cancérologie. [Oncology for medical students] B.Besse, J.Fayette, JC.Soria, E.Gyan. Collection: DCEM. 2004. Estem, Paris.
  • Cannabis and cancer – Eurocancer 2004 – John Libbey Eurotext, Paris.
  • Adult PNET – Eurocancer 2002 – John Libbey Eurotext, Paris, pp.101-102.

Others skills

Teaching activities :

– D.U. d’imagerie en oncologie, Paris XI University, Pr Y.Menu, 2005-2006 (Lung Cancer)
– D.U. de Carcinologie clinique, Paris XI University, Pr G.Vassal, 2005-on going (Non small cell lung cancer, Smal cell lung cancer)
– EFEC : Cours de chimiothérapie (Non small cell lung cancer course, chairman)
– Tutorial sessions for medical students (Conferences Hermes, Conference Aspic, Conferences plus). 2002-present.

Professional societies :

– ESMO Faculty member for the Chest Tumors 2009-2011
– IFCT (Intergroupe Francophone de Cancérologie Thoracique) : member of the steering committee since 2007
– AACR Member
– ASCO Member
– IASLC Member
– ESMO Junior Member
– President of the French Resident’s and Fellow’s Association for Teaching and Research in Oncology (AERIO). 2002-2003.

Languages :

– French, mother tongue
– English, A.L.T.E. 3.1
– Spanish, spoken

Les commentaires sont fermés.

Haut de page | Page précédente